Frailty impacts immune responses to Moderna COVID-19 mRNA vaccine in older adults
Tóm tắt
Immune responses to COVID-19 mRNA vaccines have not been well characterized in frail older adults. We postulated that frailty is associated with impaired antibody and cellular mRNA vaccine responses. We followed older adults in a retirement facility with longitudinal clinical and serological samples from the first Moderna mRNA-1273 vaccine dose starting in February 2021 through their 3rd (booster) vaccine dose. Outcomes were antibody titers, antibody avidity, and AIM+ T cell function and phenotype. Statistical analysis used linear regression with clustered error for antibody titers over multiple timepoints with clinical predictors including, age, sex, prior infection status, and clinical frailty scale (CFS) score. T cell function analysis used linear regression models with clinical predictors and cellular memory phenotype variables. Participants (n = 15) had median age of 90 years and mild, moderate, or severe frailty scores (n = 3, 7, or 5 respectively). Over the study time course, anti-spike antibody titers were 10-fold higher in individuals with lower frailty status (p = 0.001 and p = 0.005, unadjusted and adjusted for prior COVID-19 infection). Following the booster, titers to spike protein improved regardless of COVID-19 infection or degree of frailty (p = 0.82 and p = 0.29, respectively). Antibody avidity significantly declined over 6 months in all participants following 2 vaccine doses (p < 0.001), which was further impaired with higher frailty (p = 0.001). Notably, avidity increased to peak levels after the booster (p < 0.001). Overall antibody response was inversely correlated with a phenotype of immune-senescent T cells, CD8 + CD28- TEMRA cells (p = 0.036, adjusted for COVID-19 infection). Furthermore, there was increased detection of CD8 + CD28- TEMRA cells in individuals with greater frailty (p = 0.056, adjusted for COVID-19). We evaluated the immune responses to the Moderna COVID-19 mRNA vaccine in frail older adults in a retirement community. A higher degree of frailty was associated with diminished antibody quantity and quality. However, a booster vaccine dose at 6 months overcame these effects. Frailty was associated with an increased immune-senescence phenotype that may contribute to the observed changes in the vaccine response. While the strength of our conclusions was limited by a small cohort, these results are important for guiding further investigation of vaccine responses in frail older adults.
Tài liệu tham khảo
Goodwin JS, Howrey B, Zhang DD, Kuo YF. Risk of continued institutionalization after hospitalization in older adults. J Gerontol A Biol Sci Med Sci. 2011;66:1321–7. https://doi.org/10.1093/gerona/glr171.
Chidambaram P. Over 200,000 residents and staff in long-term care facilities have died from COVID-19. Kaiser Family Foundation Updated Feb 3, 2022. Accessed April 6, 2022. https://www.kff.org/policy-watch/over-200000-residents-and-staff-in-long-term-care-facilities-have-died-from-covid-19/
CMS. COVID-19 Nursing Home Data. Centers for Medicare & Medicaid Services. Accessed April 6, 2022. https://data.cms.gov/covid-19/covid-19-nursing-home-data
CDC. Risk for COVID-19 infection, hospitalization, and death by age group. Centers for Disease Control and Prevention April 6, 2022. https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-age.html#print.
Feikin DR, Higdon MM, Abu-Raddad LJ, et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022. https://doi.org/10.1016/S0140-6736(22)00152-0.
Wright BJ, Tideman S, Diaz GA, French T, Parsons GT, Robicsek A. Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study. Lancet Respir Med. 2022. https://doi.org/10.1016/S2213-2600(22)00042-X.
Richards NE, Keshavarz B, Workman LJ, Nelson MR, Platts-Mills TAE, Wilson JM. Comparison of SARS-CoV-2 antibody response by age among recipients of the BNT162b2 vs the mRNA-1273 vaccine. JAMA Netw Open. 2021;4(9):e2124331. https://doi.org/10.1001/jamanetworkopen.2021.24331.
Nordström P, Ballin M, Nordström A. Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. Lancet. 2022;399(10327):814–23. https://doi.org/10.1016/S0140-6736(22)00089-7.
Tober-Lau P, Schwarz T, Vanshylla K, et al. Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers. Lancet Respir Med. 2021;9(11):e104–5. https://doi.org/10.1016/S2213-2600(21)00456-2.
Andrew MK, Shinde V, Ye L, et al. The importance of frailty in the assessment of influenza vaccine effectiveness against influenza-related hospitalization in elderly people. J Infect Dis. 2017;216(4):405–14. https://doi.org/10.1093/infdis/jix282.
Curran D, Kim JH, Matthews S, et al. Recombinant zoster vaccine is efficacious and safe in frail individuals. J Am Geriatr Soc. 2021;69(3):744–52. https://doi.org/10.1111/jgs.16917.
Macintyre CR, Ridda I, Gao Z, et al. A randomized clinical trial of the immunogenicity of 7-valent pneumococcal conjugate vaccine compared to 23-valent polysaccharide vaccine in frail, hospitalized elderly. PLoS One. 2014;9(4):e94578. https://doi.org/10.1371/journal.pone.0094578.
Semelka CT, DeWitt ME, Callahan KE, et al. Frailty and COVID-19 mRNA Vaccine Antibody Response in The COVID-19 Community Research Partnership. J Gerontol A Biol Sci Med Sci. 2022. https://doi.org/10.1093/gerona/glac095.
Antonelli M, Penfold RS, Merino J, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID symptom study app: a prospective, community-based, nested, case-control study. Lancet Infect Dis. 2022;22(1):43–55. https://doi.org/10.1016/S1473-3099(21)00460-6.
Shapiro JR, Sitaras I, Park HS, et al. Association of Frailty, Age, and Biological Sex With Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine–Induced Immunity in Older Adults. Clin Infect Dis. 2022;75(Supplement_1):S61–71. https://doi.org/10.1093/cid/ciac397.
White EM, Yang X, Blackman C, Feifer RA, Gravenstein S, Mor V. Incident SARS-CoV-2 infection among mRNA-vaccinated and unvaccinated nursing home residents. N Engl J Med. 2021;385(5):474–6. https://doi.org/10.1056/NEJMc2104849.
Chen LK. COVID-19 vaccination and frailty in older adults. Arch Gerontol Geriatr. 2021;96:104487. https://doi.org/10.1016/j.archger.2021.104487.
Gao J, Lun P, Ding YY, George PP. COVID-19 vaccination for frail older adults in Singapore - rapid evidence summary and Delphi consensus statements. J Frailty Aging. 2022. https://doi.org/10.14283/jfa.2022.12.
Nanduri S, Pilishvili T, Derado G, et al. Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (Delta) variant - National Healthcare Safety Network, march 1-august 1, 2021. MMWR Morb Mortal Wkly Rep. 2021;70(34):1163–6. https://doi.org/10.15585/mmwr.mm7034e3.
Canaday DH, Carias L, Oyebanji OA, et al. Reduced BNT162b2 messenger RNA vaccine response in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-naive nursing home residents. Clin Infect Dis. 2021;73(11):2112–5. https://doi.org/10.1093/cid/ciab447.
Salmeron Rios S, Mas Romero M, Cortes Zamora EB, et al. Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A study. J Am Geriatr Soc. 2021;69(6):1441–7. https://doi.org/10.1111/jgs.17153.
Sanchez-Sendra B, Albert E, Zulaica J, et al. Neutralizing antibodies against SARS-CoV-2 variants of concern elicited by the comirnaty COVID-19 vaccine in nursing home residents. Sci Rep. 2022;12(1):3788. https://doi.org/10.1038/s41598-022-07849-2.
Albert E, Burgos JS, Peiro S, et al. Immunological response against SARS-CoV-2 following full-dose administration of Comirnaty(R) COVID-19 vaccine in nursing home residents. Clin Microbiol Infect. 2022;28(2):279–84. https://doi.org/10.1016/j.cmi.2021.09.031.
Jeffery-Smith A, Rowland TAJ, Patel M, et al. Reinfection with new variants of SARS-CoV-2 after natural infection: a prospective observational cohort in 13 care homes in England. Lancet Healthy Longev. 2021;2:e811–9. https://doi.org/10.1016/S2666-7568(21)00253-1.
Abbatecola AM, Incalzi RA, Malara A, et al. Monitoring COVID-19 vaccine use in Italian long term care centers: The GeroCovid VAX study. Vaccine. 2022;40(15):2324–30. https://doi.org/10.1016/j.vaccine.2022.02.064.
Demaret J, Corroyer-Simovic B, Alidjinou EK, et al. Impaired functional T-cell response to SARS-CoV-2 after two doses of BNT162b2 mRNA vaccine in older people. Front Immunol. 2021;12:778679. https://doi.org/10.3389/fimmu.2021.778679.
Seiffert P, Konka A, Kasperczyk J, et al. Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in older residents of a long-term care facility: relation with age, frailty and prior infection status. Biogerontology. 2022;23(1):53–64. https://doi.org/10.1007/s10522-021-09944-9.
Howlett SE, Rutenberg AD, Rockwood K. The degree of frailty as a translational measure of health in aging. Nature Aging. 2021;1(8):651–65. https://doi.org/10.1038/s43587-021-00099-3.
Fried LP, Xue QL, Cappola AR, et al. Nonlinear multisystem physiological dysregulation associated with frailty in older women: implications for etiology and treatment. J Gerontol A Biol Sci Med Sci. 2009;64:1049–57. https://doi.org/10.1093/gerona/glp076.
Pajewski NM, Lenoir K, Wells BJ, Williamson JD, Callahan KE. Frailty screening using the electronic health record within a Medicare accountable care organization. J Gerontol A Biol Sci Med Sci. 2019;74(11):1771–7. https://doi.org/10.1093/gerona/glz017.
Clegg A, Young J, Iliffe S, Rikkert MO, Rockwood K. Frailty in elderly people. Lancet. 2013;381(9868):752–62. https://doi.org/10.1016/S0140-6736(12)62167-9.
Kojima G. Frailty as a predictor of nursing home placement among community-dwelling older adults: a systematic review and Meta-analysis. J Geriatr Phys Ther. 2018;41(1):42–8. https://doi.org/10.1519/JPT.0000000000000097.
Rockwood K, Abeysundera MJ, Mitnitski A. How should we grade frailty in nursing home patients? J Am Med Dir Assoc. 2007;8(9):595–603. https://doi.org/10.1016/j.jamda.2007.07.012.
Dumitrascu F, Branje KE, Hladkowicz ES, Lalu M, McIsaac DI. Association of frailty with outcomes in individuals with COVID-19: a living review and meta-analysis. J Am Geriatr Soc. 2021;69(9):2419–29. https://doi.org/10.1111/jgs.17299.
Pranata R, Henrina J, Lim MA, et al. Clinical frailty scale and mortality in COVID-19: a systematic review and dose-response meta-analysis. Arch Gerontol Geriatr. 2021;93:104324. https://doi.org/10.1016/j.archger.2020.104324.
Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173(5):489–95. https://doi.org/10.1503/cmaj.050051.
Rockwood K, Mitnitski A. Frailty in relation to the accumulation of deficits. J Gerontol A Biol Sci Med Sci. 2007;62(7):722–7. https://doi.org/10.1093/gerona/62.7.722.
Geriatric Medicine Research C, Covid C, Welch C. Age and frailty are independently associated with increased COVID-19 mortality and increased care needs in survivors: results of an international multi-Centre study. Age Ageing. 2021;50(3):617–30. https://doi.org/10.1093/ageing/afab026.
Boraschi D, Aguado MT, Dutel C, et al. The gracefully aging immune system. Sci Transl Med. 2013;5(185):185ps8. https://doi.org/10.1126/scitranslmed.3005624.
Frasca D, Blomberg BB. Aging induces B cell defects and decreased antibody responses to influenza infection and vaccination. Immun Ageing. 2020;17(1):37. https://doi.org/10.1186/s12979-020-00210-z.
Goronzy JJ, Weyand CM. Mechanisms underlying T cell ageing. Nat Rev Immunol. 2019;19(9):573–83. https://doi.org/10.1038/s41577-019-0180-1.
Whiting CC, Siebert J, Newman AM, et al. Large-scale and comprehensive immune profiling and functional analysis of Normal human aging. PLoS One. 2015;10(7):e0133627. https://doi.org/10.1371/journal.pone.0133627.
Koch S, Larbi A, Derhovanessian E, Ozcelik D, Naumova E, Pawelec G. Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people. Immun Ageing. 2008;5:6. https://doi.org/10.1186/1742-4933-5-6.
Herati RS, Reuter MA, Dolfi DV, et al. Circulating CXCR5+PD-1+ response predicts influenza vaccine antibody responses in young adults but not elderly adults. J Immunol. 2014;193(7):3528–37. https://doi.org/10.4049/jimmunol.1302503.
Saurwein-Teissl M, Lung TL, Marx F, et al. Lack of antibody production following immunization in old age: association with CD8(+)CD28(−) T cell clonal expansions and an imbalance in the production of Th1 and Th2 cytokines. J Immunol. 2002;168(11):5893–9. https://doi.org/10.4049/jimmunol.168.11.5893.
Goronzy JJ, Fulbright JW, Crowson CS, Poland GA, O'Fallon WM, Weyand CM. Value of immunological markers in predicting responsiveness to influenza vaccination in elderly individuals. J Virol. 2001;75(24):12182–7. https://doi.org/10.1128/JVI.75.24.12182-12187.2001.
Mannick JB, Del Giudice G, Lattanzi M, et al. mTOR inhibition improves immune function in the elderly. Sci Transl Med. 2014;6(268):268ra179. https://doi.org/10.1126/scitranslmed.3009892.
Yousefzadeh MJ, Flores RR, Zhu Y, et al. An aged immune system drives senescence and ageing of solid organs. Nature. 2021;594(7861):100–5. https://doi.org/10.1038/s41586-021-03547-7.
Kirkwood TB. Understanding the odd science of aging. Cell. 2005;120(4):437-447. https://doi.org/10.1016/j.cell.2005.01.027
Goronzy JJ, Weyand CM. Successful and Maladaptive T Cell Aging. Immunity. 2017;46(3):364–78. https://doi.org/10.1016/j.immuni.2017.03.010.
Pinti M, Appay V, Campisi J, et al. Aging of the immune system: focus on inflammation and vaccination. Eur J Immunol. 2016;46:2286–301. https://doi.org/10.1002/eji.201546178.
Ng TP, Camous X, Nyunt MSZ, et al. Markers of T-cell senescence and physical frailty: insights from Singapore longitudinal ageing studies. NPJ Aging Mech Dis. 2015;1:15005. https://doi.org/10.1038/npjamd.2015.5.
Goel RR, Painter MM, Apostolidis SA, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 2021;374(6572):abm0829. https://doi.org/10.1126/science.abm0829.
Inoue T, Shinnakasu R, Kurosaki T. Generation of high quality memory B cells. Front Immunol. 2021;12:825813. https://doi.org/10.3389/fimmu.2021.825813.
Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. N Engl J Med. 2021;384(6):533–40. https://doi.org/10.1056/NEJMoa2034545.
Widge AT, Rouphael NG, Jackson LA, et al. Durability of responses after SARS-CoV-2 mRNA-1273 vaccination. N Engl J Med. 2021;384(1):80–2. https://doi.org/10.1056/NEJMc2032195.
Iob A, Brianti G, Zamparo E, Gallo T. Evidence of increased clinical protection of an MF59-adjuvant influenza vaccine compared to a non-adjuvant vaccine among elderly residents of long-term care facilities in Italy. Epidemiol Infect. 2005;133(4):687–93. https://doi.org/10.1017/s0950268805003936.
Dyer AH, Noonan C, McElheron M, et al. Previous SARS-CoV-2 infection, age, and frailty are associated with 6-month vaccine-induced anti-spike antibody titer in nursing home residents. J Am Med Dir Assoc Mar 2022;23(3):434-439. :https://doi.org/10.1016/j.jamda.2021.12.001.
Abbasi J. The flawed science of antibody testing for SARS-CoV-2 immunity. JAMA. 2021;326(18):1781–2. https://doi.org/10.1001/jama.2021.18919.
Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205-1211. https://doi.org/10.1038/s41591-021-01377-8.
Gruell H, Vanshylla K, Weber T, Barnes CO, Kreer C, Klein F. Antibody-mediated neutralization of SARS-CoV-2. Immunity. 2022;55(6):925–44. https://doi.org/10.1016/j.immuni.2022.05.005.
Klasse PJ. How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses. Expert Rev Vaccines. 2016;15(3):295–311. https://doi.org/10.1586/14760584.2016.1128831.
Correa VA, Rodrigues TS, Portilho AI, Trzewikoswki de Lima G, De Gaspari E. Modified ELISA for antibody avidity evaluation: the need for standardization. Biom J. 2021;44(4):433–8. https://doi.org/10.1016/j.bj.2020.10.009.
Kim W, Zhou JQ, Horvath SC, et al. Germinal Centre-driven maturation of B cell response to mRNA vaccination. Nature. 2022;604(7904):141–5. https://doi.org/10.1038/s41586-022-04527-1.
Skelly DT, Harding AC, Gilbert-Jaramillo J, et al. Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. Nat Commun. 2021;12(1):5061. https://doi.org/10.1038/s41467-021-25167-5.
Gustafson CE, Kim C, Weyand CM, Goronzy JJ. Influence of immune aging on vaccine responses. J Allergy Clin Immunol. 2020;145(5):1309–21. https://doi.org/10.1016/j.jaci.2020.03.017.
Rodda LB, Netland J, Shehata L, et al. Functional SARS-CoV-2-specific immune memory persists after mild COVID-19. Res Sq. 2020. https://doi.org/10.21203/rs.3.rs-57112/v1.
Tarke A, Sidney J, Kidd CK, et al. Comprehensive analysis of T cell immunodominance and immunoprevalence of SARS-CoV-2 epitopes in COVID-19 cases. Cell Rep Med. 2021;2(2):100204. https://doi.org/10.1016/j.xcrm.2021.100204.
Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020;181(7):1489–1501.e15. https://doi.org/10.1016/j.cell.2020.05.015.
Romero-Olmedo AJ, Schulz AR, Hochstätter S, et al. Dynamics of humoral and T-cell immunity after three BNT162b2 vaccinations in adults older than 80 years. Lancet Infect Dis. 2022;22(5):588–9. https://doi.org/10.1016/S1473-3099(22)00219-5.
Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036–1045 e9. https://doi.org/10.1016/j.cell.2020.04.026.
Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184(4):861–80. https://doi.org/10.1016/j.cell.2021.01.007.
Rydyznski Moderbacher C, Ramirez SI, Dan JM, et al. Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity. Cell. 2020;183(4):996–1012 e19. https://doi.org/10.1016/j.cell.2020.09.038.
Saggau C, Martini GR, Rosati E, et al. The pre-exposure SARS-CoV-2-specific T cell repertoire determines the quality of the immune response to vaccination. Immunity. 2022;55(10):1924–1939.e5. https://doi.org/10.1016/j.immuni.2022.08.003.
Andrew MK, McElhaney JE. Age and frailty in COVID-19 vaccine development. Lancet. 2021;396(10267):1942–4. https://doi.org/10.1016/S0140-6736(20)32481-8.
Stadlbauer D, Amanat F, Chromikova V, et al. SARS-CoV-2 seroconversion in humans: a detailed protocol for a serological assay, antigen production, and test setup. Current Protocols in Microbiology. 2020;57(1). https://doi.org/10.1002/cpmc.100.
Gluck V, Tydykov L, Mader AL, et al. Humoral immunity in dually vaccinated SARS-CoV-2-naive individuals and in booster-vaccinated COVID-19-convalescent subjects. Infection. 2022. https://doi.org/10.1007/s15010-022-01817-8.
Clemens E, Angeletti D, Holbrook BC, et al. Influenza-infected newborn and adult monkeys exhibit a strong primary antibody response to hemagglutinin stem. JCI Insight. 2020;5(5). https://doi.org/10.1172/jci.insight.135449.
Dan JM, Lindestam Arlehamn CS, Weiskopf D, et al. A cytokine-independent approach to identify antigen-specific human germinal center T follicular helper cells and rare antigen-specific CD4+ T cells in blood. J Immunol. 2016;197(3):983–93. https://doi.org/10.4049/jimmunol.1600318.
Boucher N, Dufeu-Duchesne T, Vicaut E, Farge D, Effros RB, Schächter F. CD28 expression in T cell aging and human longevity. Exp Gerontol. 1998;33(3):267–82. https://doi.org/10.1016/s0531-5565(97)00132-0.
Sasaki S, Sullivan M, Narvaez CF, et al. Limited efficacy of inactivated influenza vaccine in elderly individuals is associated with decreased production of vaccine-specific antibodies. J Clin Invest. 2011;121(8):3109–19. https://doi.org/10.1172/jci57834.
Lin D-Y, Gu Y, Xu Y, et al. Association of Primary and Booster Vaccination and prior infection with SARS-CoV-2 infection and severe COVID-19 outcomes. JAMA. 2022;328(14):1415–26. https://doi.org/10.1001/jama.2022.17876.
Fulop T, Larbi A, Pawelec G, et al. Immunosenescence and altered vaccine efficiency in older subjects: a myth difficult to change. Vaccines. 2022;10(4):607.
Rodda LB, Morawski PA, Pruner KB, et al. Imprinted SARS-CoV-2-specific memory lymphocytes define hybrid immunity. Cell. 2022;185(9):1588–1601.e14. https://doi.org/10.1016/j.cell.2022.03.018.
Duggal NA, Pollock RD, Lazarus NR, Harridge S, Lord JM. Major features of immunesenescence, including reduced thymic output, are ameliorated by high levels of physical activity in adulthood. Aging Cell. 2018;17(2):e12750. https://doi.org/10.1111/acel.12750.